| 1. |
Travis WD, Brambilla E, Muller-Hermelink HK, et a1. World Health Organization classification of tumours. Pathology ＆genetics tumours of the lung, pleural, thymus and heart. Lyon: IARC Press, 2004．.
|
| 2. |
de Klerk NH, Olsen N, Threlfall T, et al. Mesothelioma survival in Western Australia. Perth: 1st Perth Mesothelioma Centre Symposium, 2004.
|
| 3. |
Robinson BWS, MuskAW, Lake RA. Malignant Mesothelioma. Lancet, 2005, 366(9483): 397-408.
|
| 4. |
Sterman D, Albelda S. Advances in the diagnosis, evaluation and management of malignant pleural mesothelioma. Respirology, 2005, 10(3): 266-283.
|
| 5. |
Steele JPC, Klabatsa A. Chemotherapy options and new advances in malignant pleural mesothelioma. Ann Oncol, 2005, 16(3): 345-351.
|
| 6. |
van Meerbeeck JP, Baas P, Debruyne C, et al. A phase II EORTC study of temozolomide in patients with malignant pleural mesothelioma. Eur J Cancer, 2002, 38(6): 779-783.
|
| 7. |
Berghmans T, Paesmans M, Lalami Y, et al. Activity of chemotherapy and immunotherapy on malignant mesothelioma: A systematic review of the literature with meta-analysis. Lung Cancer, 2002, 38(2): 111-121.
|
| 8. |
Jackman AL, Taylor GA, Gibson W, et al. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: A new agent for clinical study. Cancer Res, 1991, 51(20): 5579-5586.
|
| 9. |
Baas P, Ardizzoni A, Grossi F, et al. The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: An EORTC phase II study (08992). Eur J Cancer, 2003, 39(3): 353-357.
|
| 10. |
Fizazi K, Doubre H, Le Chevalier T, et al. Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: Results of a phase II study. J Clin Oncol, 2003, 21(2): 349-354.
|
| 11. |
van Meerbeeck JP, Gaafar R, Manegold C, et al. Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma: An Intergroup Study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol, 2005, 23(28): 6881-6889.
|
| 12. |
Alderson P, Green S, Higgins JPT. Cochrane Reviews Handbook 4.2.6 [Update September 2006]. Available from: URL: http://www.cochrane.org/resources/handbook/.
|
| 13. |
Bottomley A, Gaafar R, Manegold C, et al. Short-term treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study. J Clin Oncol, 2006, 24(9): 1435-1442.
|
